Uveitis during treatment of disseminated Mycobacterium avium-intracellulare complex infection with the combination of rifabutin, clarithromycin and ethambutol

Netherlands Journal of Medicine

Volumn 48, Issue 6, 1996, Pages 211-214

  Lowe, S H ^a   Kroon, F P ^a   Bollemeyer, J G ^a   Stricker, B H Ch ^b   Van't Wout, J W ^a,c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Netherlands Ctr Monitoring A   (Netherlands)

^c MEDICAL CENTER HAAGLANDEN   (Netherlands)

Author keywords

Adverse effects; Drug interactions; Mycobacterium avium intracellulare complex; Rifabutin; Uveitis

Indexed keywords

CLARITHROMYCIN; CYTOCHROME P450; ETHAMBUTOL; RIFABUTIN;

ADULT; ARTHRALGIA; ARTHRITIS; ARTICLE; CASE REPORT; DRUG EXCRETION; DRUG METABOLISM; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; JAUNDICE; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM AVIUM; RASH; UVEITIS;

EID: 0029882382     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: 10.1016/0300-2977(95)00099-2     Document Type: Article

References (35)

1. Young LS. Atypical mycobacteria. In: Broder S, Merigan Jr ThC, Bolognesi D, eds. Textbook of AIDS medicine. Baltimore: Williams & Wilkins Co., 1994:283-294.
2. Benson CA. Treatment of disseminated disease due to the Mycobacterium avium complex in patients with AIDS. Clin Infect Dis 1994;18(suppl 3):S237-S242.
3. Rastogi N, Labrousse V. Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex. Antimicrob Agents Chemother 1991;35:462-470.
4. Heifets LB, Iseman MD. Determination of in vitro susceptibility of mycobacteria to ansamycin. Am Rev Respir Dis 1985;132:710-711.
5. Sullam PM, Gordin FM, Wynne BA, the Rifabutin Treatment Group. Efficacy of rifabutin in the treatment of disseminated infection due to Mycobacterium avium complex. Clin Infect Dis 1994;19:84-86.
6. Nightingale SD, Cameron DW, Gordin FM, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993;329:828-833.
7. Dautzenberg B, Truffot C, Legris S, et al. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome: a controlled clinical trial. Am Rev Respir Dis 1991;144:564-569.
8. Barradell LB, Plosker GL, McTavish D. Clarithromycin. A review of its pharmacological properties and therapeutic use in Mycobacterium avium-intracellulare complex infection in patients with acquired immune deficiency syndrome. Drugs 1993;46:289-312.
9. Shafran SD, Deschênes J, Miller M, Phillips P, Toma E. The MAC study group of the Canadian HIV trials network. Uveitis and pseudojaundice during a regimen of clarithromycin, rifabutin, and ethambutol. N Engl J Med 1994;330:438-439.
10. Letter from Kabi-Pharmacia, The Netherlands, 16-2-1994.
11. Fuller JD, Stanfield LED, Craven DE. Rifabutin prophylaxis and uveitis. N Engl J Med 1994;330:1315-1316.
12. Saran BR, Maguire AM, Nichols C, Frank I, Hertle RW, Brucker AJ. Hypopyon uveitis in patients with acquired immunodeficiency syndrome treated for systemic Mycobacterium avium complex infection with rifabutin. Arch Ophthalmol 1994;112:1159-1165.
13. Anonymous. Uveitis associated with rifabutin therapy. Morbid Mortal Weekly Rep 1994;43:658.
14. Havlir D, Torriani F, Dubé M. Uveitis associated with rifabutin prophylaxis. Ann Intern Med 1994;12:510-512.
15. Smith DK, Neal JJ, Holmberg SD, the Centers for Disease Control idiopathic CD4+ T-lymphocytopenia Task Force. Unexplained opportunistic infections and CD4+ T-lymphocytopenia without HIV infection. N Engl J Med 1993;328:373-379.
16. Siegel FP, Eilbott D, Burger H, Gehan K, Davidson B, Kaell AT, Weiser B. Dose-limiting toxicity of rifabutin in AIDS-related complex: syndrome of arthralgia/arthritis. AIDS 1990;4:433-441.
17. Niessen AGJE, Bollemeijer JG, de Keizer RJW, Meijer PHEM de Diagnostiek van systemische oorzaken van uveitis;een zaak van oogarts en internist. Ned Tijdschr Geneeskd 1994;138:770-775.
18. Spindler E, Deplus S, Flageul B. Uvéites aiguës au course des réactions de réversion. Acta Leprol 1991;7:331-334.
19. Anonymous. Pre-licensing indication for rifabutin. Lancet 1992;339:924-925.
20. Morris JT, Kelly JW. Rifabutin-induced ageusia. Ann Int Med 1993;119:171-172.
21. Skinner MH, Hsieh M, Torseth J, et al. Pharmacokinetics of rifabutin. Antimicrob Agents Chemother 1989;33:1237-1241.
22. Ohmori S, Ishii I, Kuriya S, et al. Effects of clarithromycin and its metabolites on the mixed function oxidase system in hepatic microsomes of rats. Drug Metab Disposit Biol Fate Chem 1993;21:358-363.
23. The DATRI 001 Study Group. Coadministration of clarithromycin (CL) alters the concentration-time profile of rifabutin (RFB). In: Abstracts, 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), October 1994, Orlando, FL, USA, Abstract A2.
24. Trapnell CB, Narang PK, Li R, Lewis R, Colborn D, Lavelle J. Fluconazole (Flu) increases rifabutin (Rif) absorption in HIV (+) patients on stable zidovudine (ZDV) therapy. In: Abstracts, 9th International Conference on AIDS, June 1993, Berlin, Germany, Abstract P0-B31-2212.
25. Narang PK, Trapnell CB, Schoenfelder JR, Lavelle JP, Bianchine JR. Fluconazole and enhanced effect of rifabutin profylaxis. N Engl J Med 1994;330:1316-1317.
26. Hanauer G. A new and simple method to test drug interactions with metabolic enzymes of rats in vivo. Methods Find Exp Clin Pharmacol 1990;12:557-562.
27. Shen WW, Lin KM Cytochrome P-450 monooxygenases and interactions of psychotropic drugs. Int J Psychiatry Med 1991;21:47-56.
28. Beckenridge A. Clinical significance of interactions with antifungal agents. Br J Dermatol 1992;126(suppl 39):19-22.
29. Correia MA, Castagnoli Jr N. Drug biotransformation. In: Katzung BG, ed. Basic and clinical pharmacology, 4th edn. London: Prentice-Hall International Inc., 1989:41-51.
30. In: Dollery C, ed. Therapeutic drugs. Edinburgh: Churchill Livingstone, 1991:R23-R29.
31. In: Farmacotherapeutisch Kompas 1994:613-614.
32. Opravil M, Haefner M, Kissling P, Pfyffer GE, Lüthy R. Prospective study of rifabutin, clarithromycin, and clofazimine for treatment of disseminated MAC infection. In: Abstracts 35 th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 1995, San Francisco, CA, Abstract 1203.
33. Gordin F, Wynne B, Schoenfelder J, Bailey B, Foard K, Sullam P. Uveitis not reported following dose reduction of rifabutin in ongoing study for the treatment of Mycobacterium avium complex (MAC), 087250: rifabutin (RBT) or placebo (PLA) plus clarithromycin (CLA) and ethambutol (ETH). In: Abstracts 35 th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 1995, San Francisco, CA, Abstract 1208.
34. Shafran SD, Singer J, and the MAC study group. Uveitis in AIDS patients with MAC decreases markedly at lower rifabutin doses in combination with ethambutol and clarithromycin. In: Abstracts 35 th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 1995, San Francisco, CA, Abstract 1209.
35. Griffith DE, Brown BA, Girard WM, Wallace J Jr. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin Infect Dis 1995;21:594-598.